And You Thought Biotech Was Risky
This article was originally published in Start Up
Executive Summary
Given the enormous proposed market caps on drugstore.com's and PlanetRx's IPOs, you could be forgiven for inferring that the Internet pharmacies are as close to a real business as anything to come out of Silicon Valley's dream factory. But you'd be wrong. Risks abound. And one big problem is access to reimbursed patients. Drugstore.com's costly deal with Rite Aid shows just how much the Internet pharmacy was willing to pay, both in terms of dilution and strategic flexibility, to get a solid connection with patients who have drug benefits.
You may also be interested in...
Commercializing Rare Disease Therapies Is Getting Tougher
For an industry increasingly dominated by these drugs, commercial programs need to take on the risk once reserved for development.
Paying for Pharmaceutical Value: The Problem of a One-Size-Fits-All Definition
It is a world, at least the US corner of it, in which any common understanding of drug value is confused by opposing incentives – to opacity and transparency, to looking at benefit broadly or narrowly, long-term or short-term: value, in short, to whom?
A Learning Lab For Outcomes-Based Risk-Sharing Agreements
Merck and UnitedHealth's Optum group have partnered to explore various value constructs.